IRIS
CONTEDUCA, VINCENZA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1.566
NA - Nord America 850
AS - Asia 282
SA - Sud America 7
AF - Africa 3
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 3
Totale 2.714
Salva come PNG Salva come JPEG
Nazione #
IE - Irlanda 1.080
US - Stati Uniti d'America 847
SE - Svezia 264
CN - Cina 132
SG - Singapore 121
IT - Italia 111
DE - Germania 25
UA - Ucraina 25
GB - Regno Unito 19
FI - Finlandia 16
IN - India 8
ES - Italia 6
CL - Cile 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AU - Australia 3
CO - Colombia 3
PK - Pakistan 3
TR - Turchia 3
TW - Taiwan 3
BD - Bangladesh 2
CZ - Repubblica Ceca 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
FR - Francia 2
GR - Grecia 2
HK - Hong Kong 2
JP - Giappone 2
NL - Olanda 2
RO - Romania 2
SK - Slovacchia (Repubblica Slovacca) 2
VN - Vietnam 2
AE - Emirati Arabi Uniti 1
AT - Austria 1
CA - Canada 1
CH - Svizzera 1
IQ - Iraq 1
LT - Lituania 1
MD - Moldavia 1
NO - Norvegia 1
NP - Nepal 1
PL - Polonia 1
RU - Federazione Russa 1
SA - Arabia Saudita 1
SM - San Marino 1
ZA - Sudafrica 1
Totale 2.714
Salva come PNG Salva come JPEG
Città #
Dublin 1.078
Nyköping 208
Chandler 146
Princeton 128
Wilmington 126
Singapore 83
Ashburn 58
Des Moines 23
Jacksonville 15
Munich 13
New York 13
Shanghai 13
Helsinki 12
Nanjing 11
Beijing 10
Guangzhou 10
London 10
Nocera Inferiore 10
Norwalk 9
Trento 9
Dearborn 7
Wuhan 7
Madrid 5
Potenza 5
Pune 5
Stevenage 5
Bari 4
Cagliari 4
Foggia 4
Jiaxing 4
Santa Maria a Monte 4
Washington 4
Aprilia 3
Houston 3
Islamabad 3
Los Angeles 3
Milan 3
Palermo 3
Ravenna 3
Redmond 3
Rui'an 3
San Mateo 3
Taipei 3
Bitonto 2
Bolton 2
Brno 2
Changsha 2
Chicago 2
Clearwater 2
Detva 2
Hanover 2
Hebei 2
Nanchang 2
Reston 2
Rome 2
Santiago de los Caballeros 2
Shenzhen 2
Sétif 2
Tianjin 2
Viadana 2
Vicenza 2
Wuxi 2
Xuzhou 2
Yiwu 2
Zhengzhou 2
Adliswil 1
Amsterdam 1
Andover 1
Ann Arbor 1
Athens 1
Auburn 1
Barsinghausen 1
Basra 1
Boardman 1
Bogotá 1
Borgo Maggiore 1
Brescia 1
Buffalo 1
Bussolengo 1
Calitri 1
Central 1
Cesena 1
Changchun 1
Chestnut Hill 1
Chisinau 1
Chongqing 1
Desio 1
Dong Ket 1
Dubai 1
Forlimpopoli 1
Fuzhou 1
Geislingen an der Steige 1
Groningen 1
Hangzhou 1
Hanoi 1
Huzhou 1
Jalandhar 1
Jinan 1
Jinhua 1
Kathmandu 1
Totale 2.155
Salva come PNG Salva come JPEG
Nome #
Pathophysiology of HCV-Related cryoglobulinemic vasculitis: molecular, immunological and clinical analysis 125
T cell receptor variable β gene repertoire in liver and peripheral blood lymphocytes of chronically hepatitis C virus-infected patients with and without mixed cryoglobulinaemia. 66
18F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide 61
Interleukin 28B Gene Polymorphisms in Hepatitis C Virus-related Cryoglobulinemic Vasculitis 48
B-cell frequency in hepatitis C virus-related mixed cryoglobulinemia 45
Axitinib after Sunitinib in metastatic renal cancer: Preliminary results from Italian "Real-World" SAX Study 44
Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists. 41
Anogenital lichen sclerosus et atrophicus lesions in a case series of cancer patients on immunotherapy. 40
Barrett's esophagus and esophageal cancer: An overview 40
Role of the receptor for the globular domain of C1q protein in the pathogenesis of hepatitis C virus-related cryoglobulin vascular damage 40
Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide. 39
Association among metabolic syndrome, inflammation, and survival in prostate cancer 39
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: A multi-institution correlative biomarker study 38
H. pylori infection and gastric cancer: State of the art (Review) 38
Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations. 38
Androgen receptor signaling pathways as a target for breast cancer treatment 36
Biological Evolution of Castration-resistant Prostate Cancer 36
Chromogranin A is a potential prognostic marker in prostate cancer patients treated with enzalutamide 36
N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer 36
Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer 35
BRCA2-Associated Prostate Cancer in a Patient With Spinal and Bulbar Muscular Atrophy 34
AR copy number and AR signaling-directed therapies in castration-resistant prostate cancer 33
Barrett's esophagus and esophageal cancer: An overview 33
Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone 32
An update on our ability to monitor castration-resistant prostate cancer dynamics with cell-free DNA. 31
Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer 31
Association Between Early PSA Increase and Clinical Outcome in Patients Treated with Enzalutamide for Metastatic Castration Resistant Prostate Cancer 31
Cell-free DNA as a diagnostic marker for cancer: Current insights 30
Increased serum levels of the chemokine CXCL13 and up-regulation of its gene expression are distinctive features of HCV-related cryoglobulinemia and correlate with active cutaneous vasculitis 29
Pancreatic Enzyme Replacement and Nutritional Support With nab-Paclitaxel-based First-Line Chemotherapy Regimens in Metastatic Pancreatic Cancer 28
Detecting Neuroendocrine Prostate Cancer Through Tissue-Informed Cell-Free DNA Methylation Analysis 28
Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 2: Subtypes and Divergent Differentiation 27
Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis 27
PSA flare with abiraterone in patients with metastatic castration-resistant prostate cancer 27
The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: An unresolved controversy 26
Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcome 25
A comprehensive review of the role of immune checkpoint inhibitors in elderly patients affected by renal cell carcinoma. 24
Persistent neutrophil to lymphocyte ratio >3 during treatment with enzalutamide and clinical outcome in patients with castration-resistant prostate cancer 24
Safety and Clinical Outcomes of Abiraterone Acetate after Docetaxel in Octogenarians with Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme 24
Epigenetics in prostate cancer: clinical implications 24
Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: Results of the Italian Named Patient Programme 23
Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone 23
Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib 23
Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: Results of the Italian Named Patient Programme 23
Circulating tumor cells: Utopia or reality? 23
Systemic immune-inflammation index predicts the clinical outcome in patients with mCRPC treated with abiraterone 23
In reply 23
Molecular mechanisms of resistance in testicular germ cell tumors - Clinical implications 23
Circulating androgen receptor gene amplification and resistance to 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial. 22
Hepatitis C virus infection and mixed cryoglobulinemia 22
Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma 22
Metabolic syndrome as a peculiar target for management of prostate cancer patients 22
High Neutrophil-to-lymphocyte Ratio Persistent During First-line Chemotherapy Predicts Poor Clinical Outcome in Patients with Advanced Urothelial Cancer 22
Plasma Androgen Receptor Copy Number Status at Emergence of Metastatic Castration-Resistant Prostate Cancer: A Pooled Multicohort Analysis. 22
Vitamin D status among long-term survivors of testicular cancer 22
Immunotherapy and Its Development for Gynecological (Ovarian, Endometrial and Cervical) Tumors: From Immune Checkpoint Inhibitors to Chimeric Antigen Receptor (CAR)-T Cell Therapy. 22
Vitamin D Deficiency in Testicular Cancer Survivors: A Systematic Review. 22
Role of the receptor for the globular domain of C1q protein in the pathogenesis of hepatitis C virus-related cryoglobulin vascular damage 21
Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone 21
New Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer. 20
Neuroendocrine differentiation in prostate cancer: Current and emerging therapy strategies 20
Pegylated interferon-α, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: A long-term study 20
Prognostic Role of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma: A Large, Multicenter, Prospective Trial. 19
Plasma androgen receptor and serum chromogranin A in advanced prostate cancer 19
Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging. 19
Conditional survival of patients treated with first-line chemotherapy for metastatic urothelial cancer 19
Taxane-related nail toxicity 19
The emerging role of anti-angiogenic therapy in ovarian cancer (review) 19
Impact of cryoglobulinemic syndrome on the outcome of chronic hepatitis C virus infection: A 15-year prospective study 19
Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer 19
Transarterial chemoembolization plus sorafenib: A sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: A randomized clinical trial 19
Re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol 2016;70:724–31 19
Correlation of Stomatitis and Cutaneous Toxicity With Clinical Outcome in Patients With Metastatic Renal-Cell Carcinoma Treated With Everolimus 19
Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients 19
Erratum to: 18F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide [Eur J Nucl Med Mol Imaging, DOI 10.1007/s00259-015-3042-5] 19
Precancerous colorectal lesions (Review) 19
Plasma Androgen Receptor in Prostate Cancer. 19
Enzalutamide after chemotherapy in advanced castration-resistant prostate cancer: the Italian Named Patient Program 18
Circulating Androgen Receptor for Prognosis and Treatment Selection in Prostate Cancer. 18
Immunotherapy for prostate cancer: Where we are headed 18
Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment. 18
The Interplay between Inflammation, Anti-Angiogenic Agents, and Immune Checkpoint Inhibitors: Perspectives for Renal Cell Cancer Treatment. 18
Role of DNA repair machinery and p53 in the testicular germ cell cancer: A review 18
Prognostic value of 18F–choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide 18
Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer 18
The potential use of urine cell free DNA as a marker for cancer 18
Immunotherapy for prostate cancer: Where we are headed 18
Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone 18
Genome-wide plasma DNA methylation features of metastatic prostate cancer. 18
Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone 18
Talazoparib: a new biomarker-directed therapy in advanced prostate cancer 18
Targeted radioactive therapy for prostate cancer 18
Molecular mechanisms of resistance in testicular germ cell tumors - Clinical implications 18
Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer. 18
Re: Marzia Del Re, Elisa Biasco, Stefania Crucitta, et al. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. Eur Urol 2017;71:680–7 17
Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents 17
CYP17A1 polymorphisms and clinical outcome of castration-resistant prostate cancer patients treated with abiraterone 17
Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone 17
Urothelial Cancer: Inflammatory Mediators and Implications for Immunotherapy 17
Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib 17
Totale 2.666
Salva come PNG Salva come JPEG
Categoria #
all - tutte 42.307
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 42.307
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202030 0 0 0 0 6 5 5 2 8 0 4 0
2020/202131 3 0 3 0 6 2 5 0 4 4 1 3
2021/2022856 4 2 3 1 371 15 25 50 102 104 17 162
2022/20231.723 186 31 86 25 47 109 3 71 1.117 15 19 14
2023/2024222 11 19 11 19 26 77 1 21 8 7 1 21
2024/2025244 103 68 11 30 32 0 0 0 0 0 0 0
Totale 3.184